Skip to main content

Table 2 Treatment-related grade ≥ 2 adverse events

From: Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial

  Dose level 1
n = 1
2
n = 2
3
n = 0
4
n = 1
5
n = 6
6
n = 4
7
n = 3
8
n = 19
Total
N = 36
  Bevacizumab
IV q2w (mg/kg)
2.5 5 5 5 7.5 7.5 7.5 10  
  Cetuximab
IV weekly (mg/m2)*
100, 75 100, 75 200, 125 200, 125 200, 125 400, 250 400, 250 400, 250  
  Erlotinib
PO daily (mg)
50 50 50 100 100 100 150 150  
Rash
 Grade 2   0 0 0 1 3 2 0 10 16 (44%)
 Grade 3   0 0 0 0 0 0 0 4 4 (11%)
Pruritus
 Grade 2   0 0 0 1 0 0 0 1 2 (6%)
 Grade 3   0 0 0 0 0 0 0 1 2 (6%)
Diarrhea
 Grade 2   0 0 0 0 0 0 0 3 3 (8%)
Fatigue
 Grade 2   0 0 0 0 1 0 1 0 2 (6%)
Hand-foot syndrome
 Grade 2   0 0 0 0 0 0 1 0 2 (6%)
Hypomagnesemia
 Grade 2   0 0 0 0 0 0 0 2 2 (6%)
 Grade 3–4   0 0 0 0 1 0 0 3 4 (11%)
Nausea/vomiting
 Grade 2   0 0 0 0 0 0 0 1 1 (3%)
Mucositis  
 Grade 2   0 0 0 0 0 0 0 1 1 (3%)
Anorexia
 Grade 2   0 0 0 0 0 0 0 2 2 (6%)
Hypertension
 Grade 2   0 0 0 0 0 0 0 1 1 (3%)
Bleeding
 Grade 3   0 0 0 0 1 0 0 2 3 (8%)
Elevated AST/ALT
 Grade 3   0 0 0 0 0 0 0 1 1 (3%)
Anemia
 Grade 3   0 0 0 0 1 0 0 0 1 (3%)
Transvaginal fistula
 Grade 4   0 0 0 0 2 0 0 0 2 (6%)
  1. * Cetuximab dose shown as loading dose and maintenance dose